CIK 0001635088
- Large accelerated filer
Roivant Sciences Ltd.
Sign in to watch- Ticker
- ROIV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- Bermuda
- Entity type
- Operating
- EIN
- 981173944
- Phone
- +44 12955950
- Business address
- 7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $70,369,463
- in 12 filings, $45.5M under 10b5-1 plans
Net −$70,369,463. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-09 | Venker Eric President & COO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −96,950 | 12,526,234 | ||
| 2024-01-28 | Pulik Richard CFO | Shares withheld for taxes 10b5-1 | −1,896 | $10.37 | $20K | 271,183 |
| 2024-01-20 | Gline Matthew CEO | Shares withheld for taxes 10b5-1 | −10,945 | $10.35 | $113K | 1,011,953 |
| 2024-01-20 | Kumar Rakhi Chief Accounting Officer | Shares withheld for taxes 10b5-1 | −1,506 | $10.35 | $16K | 190,783 |
| 2024-01-20 | Venker Eric President & COO | Shares withheld for taxes 10b5-1 | −12,377 | $10.35 | $128K | 532,207 |
| 2024-01-19 | MOMTAZEE JAMES C Director | Grant or award | +1,570 | 76,339 | ||
| 2024-01-19 | Fitzgerald Meghan Director | Grant or award | +1,328 | 12,686 | ||
| 2024-01-19 | Epperly Melissa B, Director | Grant or award | +1,207 | 21,538 | ||
| 2024-01-19 | Oren Ilan Director | Grant or award | +3,366 | 78,342 | ||
| 2024-01-02 | Ramaswamy Vivek 10% owner | Sale | −3,000,000 | $11.05 | $33.1M | 51,929,426 |
| 2023-12-28 | Pulik Richard CFO | Shares withheld for taxes 10b5-1 | −1,913 | $11.37 | $22K | 273,079 |
| 2023-12-27 | Ramaswamy Vivek 10% owner | Option exercise 10b5-1 | +275,227 | 55,063,337 | ||
| 2023-12-27 | Ramaswamy Vivek 10% owner | Shares withheld for taxes 10b5-1 | −133,911 | $11.58 | $1.6M | 54,929,426 |
| 2023-12-27 | Ramaswamy Vivek 10% owner | Option exercise · Capped Value Appreciation Rights 10b5-1 | −611,393 | $6.40 | $3.9M | 7,132,921 |
| 2023-12-27 | Ramaswamy Vivek 10% owner | Option exercise · Capped Value Appreciation Rights 10b5-1 | −251,538 | $11.50 | $2.9M | 11,570,769 |
| 2023-12-27 | Gline Matthew CEO | Option exercise 10b5-1 | +38,453 | 1,044,941 | ||
| 2023-12-27 | Gline Matthew CEO | Shares withheld for taxes 10b5-1 | −22,043 | $11.58 | $255K | 1,022,898 |
| 2023-12-27 | Gline Matthew CEO | Option exercise · Capped Value Appreciation Rights 10b5-1 | −85,232 | $6.40 | $545K | 994,373 |
| 2023-12-27 | Gline Matthew CEO | Option exercise · Capped Value Appreciation Rights 10b5-1 | −47,351 | $11.50 | $545K | 2,178,150 |
| 2023-12-27 | Sukhatme Mayukh Pres&Chief Investment Officer | Option exercise | +71,365 | 3,289,115 |
Page 34 of 38 · 748 trades